$108.24 $0.11 (0.1%)

08:00 PM EST on 11/20/19

Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Current Price $108.24 Mkt Cap $77.0B
Open $108.01 P/E Ratio 12.97
Prev. Close $108.13 Div. (Yield) $0.00 (0.0%)
Daily Range $107.27 - $108.59 Volume 191,230,586
52-Wk Range $63.19 - $110.70 Avg. Daily Vol. 9,494,262

Caps

How do you think NASDAQ:CELG will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,177 Outperform
78 Underperform
 

All-Star Players

420 Outperform
11 Underperform
 

Wall Street

25 Outperform
1 Underperform
 

Top NASDAQ:CELG Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFPencils (99.86)
Submitted May 21, 2018

Taking a bit of a flyer on this one given the leadership shuffling going on and questions surrounding some drugs in its pipeline. But despite the near-term challenges, Celgene is still producing more than $3.7 billion in FCF annually and is now… More

NetscribeBiotech (93.82)
Submitted February 22, 2007

Celgene is a biopharmaceutical company focused on novel therapies to treat a broad range of hematopoietic, immunological, neuronal, and cancerous conditions. Celgene currently markets Thalomid for ENL and multiple myeloma, Revlimid for… More

Recent Community Commentary

Read the most recent pitches from players about CELG.

Recs

0
Member Avatar future21 (54.72) Submitted: 11/7/2018 10:26:39 PM : Outperform Start Price: $75.17 NASDAQ:CELG Score: +33.22

Strong pipeline, been watching this stock for a few years and like the recent discount. Seems like a great opportunity to buy a strong player in healthcare. I worry about the political rhetoric surrounding healthcare profits as a long-term headwind, and will watch closely to see how that might affect Celgene in the years to come. In general, healthcare is an ever-present industry and a strong pipeline, history of success, and revenue to support future research makes this a less risky pick than many of the other options. TMF's recent report on catalysts for short-term growth is also encouraging, but I'm looking for a long run based on the pipeline.

Will watch the political climate and the FDA approval process for the potential blockbusters in Celgene's pipeline as possible red flags.

Recs

0
Member Avatar tsunamied (66.56) Submitted: 11/2/2018 12:30:38 AM : Outperform Start Price: $76.21 NASDAQ:CELG Score: +29.08

BIOTECH. CRISPR. YEAH!

Recs

0
Member Avatar sojournerks (97.38) Submitted: 10/27/2018 10:25:14 AM : Outperform Start Price: $73.24 NASDAQ:CELG Score: +32.33

Good company in a good sector.

Leaderboard

Find the members with the highest scoring picks in CELG.

Score Leader

InvestorDeb

InvestorDeb (71.93) Score: +432.42

The Score Leader is the player with the highest score across all their picks in CELG.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
martyc484 < 20 9/15/2006 Outperform 3Y $20.35 +431.89% +148.14% +283.75 1 Comment
poang 37.05 9/15/2006 Outperform 3Y $20.47 +428.90% +148.72% +280.18 0 Comment
predfern 62.45 9/15/2006 Outperform 5Y $20.47 +428.90% +148.72% +280.18 1 Comment
shanedawg 85.02 9/16/2006 Outperform 1Y $20.50 +428.13% +148.16% +279.97 0 Comment
nepedal < 20 9/21/2006 Outperform 3Y $20.55 +426.72% +148.69% +278.03 1 Comment
MYSTICQUEEN 71.02 9/21/2006 Outperform 3Y $20.62 +425.05% +148.70% +276.36 0 Comment
pharmaway < 20 9/14/2006 5/6/2008 Outperform 1Y $20.55 +426.72% +151.26% +275.46 1 Comment
jolen168 < 20 9/14/2006 Outperform 3Y $20.59 +425.82% +150.71% +275.11 0 Comment
littleboyblue2 70.95 9/14/2006 Outperform 3M $20.59 +425.82% +150.71% +275.11 0 Comment
bronxboston 28.96 9/14/2006 Outperform 1Y $20.59 +425.82% +150.71% +275.11 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CELG.